Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Medicamen Biotech has informed that it enclosed details of related party transactions on consolidated basis for the half year ended on September 30, 2022.
The above information is a part of company’s filings submitted to BSE.